ubiquinone and mevalonolactone

Canventol, a synthetic compound, is a new inhibitor of tumor promotion on mouse skin by okadaic acid. We previously reported that canventol acts by inhibiting both protein isoprenylation and tumor necrosis factor-alpha (TNF-alpha) release. In this study we examined the potencies of 10 newly synthesized canventol analogs through their effect on mevalonate metabolism, and then examined 3 representative analogs for inhibition of protein isoprenylation. Since canventol in vitro did not directly inhibit farnesyl protein transferase or geranylgeranyl protein transferase-I, the effects of canventol and its synthetic analogs on the fate of [3H]mevalonate in cells were studied. Canventol at 500 microM changed the ratio of newly synthesized sterols (cholesterol and lathosterol) to ubiquinones from 0.7 to 8.2 in NIH/3T3 cells which had previously been labeled with [3H]mevalonate, suggesting that the altered pattern of mevalonate metabolism is associated with inhibition of protein isoprenylation in the cells. We named this ratio the inhibition of protein isoprenylation index (IPI index). The 10 analogs showed a wide range of IPI indices. Two analogs, S3 and S9 had effects similar to, or stronger than, canventol. Three analogs, C44, C46 and C47, with lower IPI indices, inhibited tumor promotion on mouse skin slightly less than canventol itself did. This study shows that inhibition of protein isoprenylation in the cells, indicated by an increase in the IPI index, is a new biomarker for estimating inhibition of tumor promotion.

Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Anticarcinogenic Agents; Carcinogens; Cyclohexanols; Enzyme Inhibitors; Female; Lipid Metabolism; Mevalonic Acid; Mice; Mice, Inbred Strains; Okadaic Acid; Protein Prenylation; Skin Neoplasms; Sterols; Transferases; Ubiquinone

Evidence has been obtained indicating that free farnesol (F-OH) can be utilized for isoprenoid biosynthesis in mammalian cells. When rat C6 glial cells and an African green monkey kidney cell line (CV-1) were incubated with [3H]F-OH, radioactivity was incorporated into cholesterol, ubiquinone (CoQ) and isoprenylated proteins. The incorporation of label from [3H]F-OH into cholesterol in C6 and CV-1 cells was blocked by squalestatin 1 (SQ) which specifically inhibits the conversion of farnesyl pyrophosphate (F-P-P) to squalene. This result strongly suggests that cholesterol, and probably CoQ and protein, is metabolically labeled via F-P-P. SDS-PAGE analysis of the delipidated protein fractions from C6 and CV-1 cells revealed several labeled polypeptides. Consistent with these proteins being modified by isoprenylation of cysteine residues. Pronase E digestion released a major labeled product with the chromatographic mobility of [3H]farnesyl-cysteine (F-Cys). A different set of polypeptides was labeled when C6 and CV-1 cells were incubated with [3H]geranylgeraniol (GG-OH). Both sets of proteins appear to be metabolically labeled by [3H]mevalonolactone, and [3H]-labeled F-Cys and geranylgeranyl-cysteine (GG-Cys) were liberated from these proteins by Pronase E treatment. These cellular and biochemical studies indicate that F-OH can be used for isoprenoid biosynthesis and protein isoprenylation in mammalian cells after being converted to F-P-P by phosphorylation reactions that remain to be elucidated.

Topics: Animals; Cell Line; Chlorocebus aethiops; Cholesterol; Cysteine; Diterpenes; Electrophoresis, Polyacrylamide Gel; Farnesol; Glioma; Kinetics; Mevalonic Acid; Neoplasm Proteins; Protein Biosynthesis; Protein Prenylation; Proteins; Rats; Tritium; Tumor Cells, Cultured; Ubiquinone

When rat liver slices were incubated with varying concentrations of [3H]mevalonolactone, the chain lengths of radiolabeled dolichyl phosphate and ubiquinone varied according to the initial mevalonolactone concentration, indicating that product chain length is dependent on the level of isoprenoid diphosphate intermediates. However, when livers were analyzed from rats which had been maintained on diets of either colestipol (which induces cholesterogenesis 3-fold), or normal chow, or cholesterol (which suppresses cholesterogenesis to 5% of normal) there were only minor changes in the isoprene distribution of either dolichyl phosphate or ubiquinone. In contrast, when rats were maintained on 2% cholesterol plus mevalonolactone (conditions prone to increase the levels of intermediates), the isoprene distributions of both of these compounds were greatly shifted to the higher homologs. However, under none of these conditions were the hepatic levels of these compounds changed significantly. It is concluded that under conditions of greatly altered cholesterogenesis, regulatory mechanisms exist which stabilize the levels of isoprenoid diphosphate intermediates, and that even when levels are increased (e.g., by dietary manipulation), the effect is only to alter isoprene distribution and not the rate of synthesis of dolichyl phosphate and ubiquinone.

Topics: Animals; Cholesterol; Dietary Fats; Dolichol Phosphates; In Vitro Techniques; Liver; Male; Mevalonic Acid; Polyisoprenyl Phosphates; Rats; Rats, Sprague-Dawley; Tritium; Ubiquinone

The biosynthetic mechanism for determining the side-chain length of ubiquinone in rat heart mitochondria was investigated. The biosynthesis of nonaprenyl ubiquinone (UQ-9) and decaprenyl ubiquinone (UQ-10) in the mitochondria from rat hearts previously perfused with mevalonolactone was accelerated depending on the concentration of mevalonolactone. Furthermore the synthesis ratio between UQ-10 and UQ-9 (UQ-10/UQ-9) increased in accordance with the increasing concentration of mevalonolactone used. In addition, an enhancement of the synthesis ratio (UQ-10/UQ-9) was observed when the rats were treated with isoproterenol to increase the activity of 3-hydroxymethylglutaryl-CoA (HMG-CoA) reductase, a rate-limiting enzyme which forms mevalonate. Moreover, the addition of isopentenyl pyrophosphate, which is a metabolite of mevalonate, elevated the synthetic ratios UQ-10/UQ-9 in intact mitochondria and decaprenyl pyrophosphate/solanesyl pyrophosphate in the partially purified polyprenyl pyrophosphate synthetase from rat heart. These results suggest that the HMG-CoA reductase could be involved as a determining factor of the side-chain length of ubiquinone in rat heart.

Topics: Animals; Diphosphates; Hemiterpenes; Hydroxymethylglutaryl CoA Reductases; Iodoacetamide; Isoproterenol; Mevalonic Acid; Mitochondria, Heart; Myocardium; Organophosphorus Compounds; Polyisoprenyl Phosphates; Rats; Rats, Inbred Strains; Terpenes; Ubiquinone

The biosynthesis of ubiquinone was studied in an isolated perfused beating heart preparation from adult male rats to determine rate-limiting steps in the biosynthetic pathway. The isolated heart could incorporate p-hydroxy[U-14C]benzoate into ubiquinones (ubiquinone-9 and -10) and two other lipids which were identified as 3-nonaprenyl 4-hydroxybenzoate and 3-decaprenyl 4-hydroxybenzoate. No other lipids could be detected. Addition of unlabeled mevalonolactone to the perfusate stimulated the rate of incorporation of p-hydroxy[U-14C]benzoate into 3-nonaprenyl 4-hydroxybenzoate and 3-decaprenyl 4-hydroxybenzoate. The level of radioactivity in these intermediates was much greater than that in ubiquinone-9 and -10. These results show that in the intact heart there is a large excess capacity to form postmevalonate isoprenoid precursors of ubiquinone and suggest a possible regulatory step at the premevalonate level. Moreover, the accumulation of prenylated derivatives of 4-hydroxybenzoic acid indicates further rate limitation at one or more of the subsequent steps in conversion of these intermediates to ubiquinone.

Topics: Animals; Enzyme Precursors; In Vitro Techniques; Lipids; Male; Methylation; Mevalonic Acid; Mitochondria, Heart; Myocardium; Parabens; Perfusion; Rats; Rats, Inbred Strains; Ubiquinone

Recently discovered metabolites in urine have suggested a defect of isoprenoid metabolism in multiple sclerosis. Lymphocyte HMG-CoA reductase was found unaffected however, and so was lymphocyte biosynthesis of geraniol, farnesol and squalene from mevalonolactone. The level of dolichol in white matter of an MS brain was similar to that of a control sample. Serum ubiquinone, on the other hand, was decreased in multiple sclerosis. Ubiquinone in serum was both age-dependent and related to serum cholesterol. Active as well as stable MS displayed a decreased level of serum ubiquinone, and a reduced ubiquinone-cholesterol ratio. These results are compatible with a deficient ubiquinone biosynthesis in multiple sclerosis.

Topics: Adult; Brain Chemistry; Butadienes; Cholesterol; Diterpenes; Hemiterpenes; Humans; Hydroxymethylglutaryl CoA Reductases; Lymphocytes; Mevalonic Acid; Multiple Sclerosis; Pentanes; Ubiquinone

Bovine milk contains two inhibitors of hepatic cholesterol genesis. One of these, identified as orotic acid, influences the early segment of the cholesterol biosynthetic pathway and suppresses the conversion of acetate to mevalonate. In this study the other inhibitor was shown to curtail the formation of compounds past farnesyl pyrophosphate on the squalene-cholesterol branch of the pathway. Thus cholesterol synthesis may be suppressed while the production of two other products of the branched pathway, dolichol and ubiquinone, is allowed to continue. The possible role of these ingested regulators in the metabolism of the young until they achieve sufficient development is discussed.

Topics: Acetates; Acetic Acid; Animals; Anticholesteremic Agents; Cattle; Cholesterol; Cholesterol, LDL; Diterpenes; Dolichols; In Vitro Techniques; Lanosterol; Lipoproteins, LDL; Liver; Mevalonic Acid; Milk; Orotic Acid; Polyisoprenyl Phosphates; Rats; Sesquiterpenes; Squalene; Ubiquinone

Ubiquinone synthesis has been studied in cultured C-6 glial and neuroblastoma cells by utilizing an inhibitor, 3-beta-(2-diethylaminoethoxy) androst-5-en-17-one hydrochloride (U18666A), of cholesterol biosynthesis. Exposure of C-6 glial cells to nanomolar quantities of U18666A caused a marked inhibition of total sterol synthesis from [14C]acetate or [3H]mevalonate within minutes. A 95% inhibition was apparent after a 3-h exposure to 200 ng/ml of U18666A. These observations, together with studies of the incorporation of radioactivity from the two precursors into cholesterol, desmosterol, lanosterol, and squalene, indicated that although the most sensitive site to inhibition by U18666A is desmosterol reduction to cholesterol, a major site of inhibition is demonstrable at a more proximal site, perhaps squalene synthetase. As a consequence of the latter inhibition, exposure of C-6 glial cells to U18666A caused a marked stimulation of incorporation of [14C]acetate or [3H]mevalonate into ubiquinone. Over a wide range of U18666A concentrations, the increase in ubiquinone synthesis was accompanied by an approximately similar decrease in total sterol synthesis. Whereas in the absence of U18666A only approximately 7% of the radioactivity incorporated from [3H]mevalonate into isoprenoid compounds was found in ubiquinone, in the presence of the drug approximately 90% of incorporated radioactivity was found in ubiquinone. The reciprocal effects of U18666A on ubiquinone and sterol syntheses were apparent also in the neuronal cells. THe data thus demonstrate a tight relationship between ubiquinone and sterol biosyntheses in cultured cells of neural origin. In such cells ubiquinone synthesis is exquisitely sensitive to the availability of isoprenoid precursors derived from the cholesterol biosynthetic pathway.

Topics: Acetates; Androstenes; Animals; Anticholesteremic Agents; Carbon Radioisotopes; Cell Line; Glioma; Kinetics; Mevalonic Acid; Neuroblastoma; Rats; Sterols; Ubiquinone

Topics: Cell Line; Cholesterol; Fibroblasts; Humans; Hydroxymethylglutaryl CoA Reductases; Kinetics; Lactones; Lipoproteins, LDL; Mevalonic Acid; Parabens; Skin; Ubiquinone